Artiva Biotherapeutics Goes Public on Nasdaq, Raising $167 Million to Advance Allogeneic NK Cell Therapies
Artiva Biotherapeutics
Cancer Treatment Drug Developer
July 20, 2024
eMedClub News
Today (U.S. time July 19), a company dedicated to developing treatments for autoimmune diseases and cancerNKCell Therapy EnterprisesArtiva Biotherapeutics Officially IPOs on NasdaqIt issued 13,920,000 ordinary shares to the public at a price of $12 per share.Approximately $167 million (approximately RMB 1.213 billion) is expected to be obtained.。
Artiva Biotherapeutics' most advanced pipeline candidate is the allogeneic NK therapy AB-101 (AlloNK), a cord blood-derived, allogeneic, cryopreserved, non-genetically modified, ADCC (antibody-dependent cell-mediated cytotoxicity)-enhanced NK cell therapy candidate. It can be used in outpatient settings in combination with monoclonal antibodies or innate cell engagers, stacking innovative "buffs" to the fullest.
▲Pipeline under research (Source: Official website)
This candidate product has progressed to Phase 2 clinical research, with ongoing clinical studies targeting diseases such as lupus nephritis (LN), rheumatoid arthritis (RA), pemphigus vulgaris (PV), and B-cell non-Hodgkin lymphoma (NHL). It can be said that Artiva's AB-101 is at a critical stage, with funds raised through the IPO.AThe development of B-101 will be more secure.。
In addition, Artiva's AlloNK™ platform enables the selection of cord blood units with the KIR-B haplotype to generate a master cell bank of NK cells, followed by large-scale NK cell expansion and activation processes based on bioreactors to produce thousands of doses of pure NK cells. These cells maintain high and consistent expression of CD16 and other tumor-activating receptors (such as NKG2D, DNAM-1, NKp30, NKp46, etc.) without requiring additional engineering. The resulting NK cells, optimized through cryopreservation techniques, ensure maximum cell viability, are suitable for long-distance logistics, and can be repeatedly administered in an outpatient setting.
▲ Production Technology (Image Source: Official Website)
At the same time, Artiva has established a research and development platform for CAR-NK, which equips NK cells with optimized CARs to enhance their therapeutic activity and tumor targeting capabilities. All CAR-NK therapies are manufactured based on the AlloNK™ platform, which maintains high expression of CD16, enabling dual-targeting therapy when combined with monoclonal antibodies. Additionally, Artiva has built a 52,000-square-foot manufacturing infrastructure to support the production of NK and CAR-NK cells. At the current scale of 50 liters, this facility is expected to produce more than 6,000 vials annually, each containing one billion cells. Artiva is currently developing a 200-liter, commercial-scale process.This process is expected to efficiently meet the needs of thousands of patients at a cost of less than $1,000 per bottle of one billion cells.。
In fact, as early as 2021, Artiva, which had been established for only two years, had previously filed an IPO application. However, 18 months later, Artiva withdrew and instead formed a partnership with Affimed. In October of last year, Artiva ended a collaboration with Merck worth up to $1.8 billion. In the 12 months ending March 31, 2024, Artiva’s collaboration and licensing revenue was $33 million, while its R&D expenses for the whole of 2023 were $50 million, and $11 million in the first quarter of this year. By the end of the first quarter of this year, Artiva had approximately $62 million in cash, cash equivalents, and short-term investments, indicating that its cash flow is not particularly abundant.This successful IPO can also bring financial support to Artiva Biotherapeutics, alleviating its financial pressure., better promote the development of its clinical products.
This again highlights that the biotechnology sector is a highly capital-intensive industry, requiring continuous funding to support research and development as well as market expansion. For biotech companies, effectively raising capital, managing funds, and optimizing the efficiency of fund utilization are crucial.The capital market is an important financing channel for biotechnology enterprises.Artiva Biotherapeutics, Inc. has chosen to enter the capital market and raise funds through an IPO, a path that many companies take.
IPO is not just a way to raise funds,This is often accompanied by extensive media coverage and investor attention, which helps to enhance Artiva's visibility and expand its market influence.For a company focused on the biotechnology sector, an increase in market recognition helps attract more partners, investors, and potential customers. A successful IPO by Artiva Biotherapeutics will also bring new attention to the industry. After the IPO, Artiva can raise additional funds through issuing new shares, bonds, and other means to support the realization of its long-term strategic goals. Going public also provides the company with more flexible capital operation tools, such as mergers and acquisitions, collaborations, etc.
Overall, the successful IPO of Artiva Biotherapeutics marks an important milestone in its development and reflects the race between funding and innovation in the biotechnology sector. The NK cell therapy track still requires more data and technical support, and we hope that companies like Artiva Biotherapeutics can continue to bring new possibilities to patients.
DianDian "Share”、“Like" and "In view", charge me up a bit~"